- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00478725
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
An Open-Label, Two-Part Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Pazopanib (GW786034) and the Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of Pazopanib in Subjects With Solid Tumor Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- GSK Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Subject must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up. Procedures conducted as part of the subject's routine clinical management (e.g., blood count, imaging study) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol.
- Has histologically or cytologically confirmed advanced solid tumor malignancy.
- For Part A: Males, age: 30 years or greater.
- For Part B: Males or Females, age: 18 years or greater.
- For Part A or B, males that meet the following criteria.
A male subject with a female partner of childbearing potential is eligible to enter and participate in this study if he:
- Agrees to use double-barrier contraception (condom with spermicidal jelly, foam, suppository or film, or a condom and his partner uses a diaphragm with spermicide), OR
- Agrees to complete abstinence from sexual intercourse for 14 days before exposure to investigational product, through the clinical trial, and for at least 21 days after the last dose of investigational product.
- For Part B, females that meet the following criteria:
A female subject is eligible to enter and participate in this study if she is of:
Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had:
- A hysterectomy
- A bilateral oophorectomy (ovariectomy)
- A bilateral tubal ligation
- Is post-menopausal (total cessation of menses for >/ 1 year), OR
Childbearing potential and has a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception. GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follows:
- An intrauterine device (IUD) with a documented failure rate of less than 1% per year.
- Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.
- Complete abstinence from sexual intercourse for 14 days before exposure to investigational product, through the clinical trial, and for at least 21 days after the last dose of investigational product.
- Double-barrier contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide).
- Note: Oral contraceptives are not considered reliable due to potential drug-drug interaction.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Body weight >/ 50 kg.
- Adequate organ systems function as defined in Table 1.
- Ability to swallow and retain oral medication.
Exclusion criteria:
- History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to beginning study treatment. Screening with CNS imaging studies (CT scan or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases.
- Clinically significant gastrointestinal (GI) abnormalities including, but not limited to: malabsorption syndrome, history of resection of the stomach or small bowel, active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis or other conditions that increase the risk for perforation, history of abdominal fistula, GI perforation or intra-abdominal abscess within 4 weeks prior to beginning study treatment.
- Presence of uncontrolled infection.
- Corrected QT interval (QTc) > 480 msec.
- History of any one or more of the following cardiovascular conditions within the past 6 months: congestive heart failure, cardiac angioplasty or stenting, myocardial infarction, unstable angina OR symptomatic peripheral vascular disease.
- Has poorly controlled hypertension (systolic blood pressure [SBP] >/ 140 mmHg, or diastolic blood pressure [DBP] >/ 90 mmHg).
- Note: Initiation or adjustment of anti-hypertensive medication(s) is permitted prior to study entry. The blood pressure (BP) must be re-assessed on 2 occasions that are separated by a minimum of 24 hours. The mean SBP/DBP values from both BP assessments must be < 140/90 mmHg in order for a subject to be eligible for the study.
- History of cerebrovascular accident or pulmonary embolism within the past 6 months.
- History of untreated deep venous thrombosis (DVT) within the past 6 months.
- Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.
- Prior major surgery or trauma within the past 28 days or presence of any wound, fracture or ulcer which is not fully healed.
- Evidence of active bleeding, bleeding diathesis or hemoptysis within 6 weeks prior to study treatment.
- Use of prohibited medications within the timeframes specified in Section 9.2, Prohibited Medications of the protocol.
- Use of an investigational agent, including an investigational anti-cancer agent within 28 days or 5 half-lives, whichever is longer, preceding the first dose of pazopanib.
- Treatment with any cancer therapy (including chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery or tumor embolization) within 14 days prior to the first dose of pazopanib.
- Note: Current treatment with leuprolide is permitted.
- Any ongoing potentially reversible toxicity from prior anti-cancer therapy that is > Grade 1 or any toxicity from prior anti-cancer therapy that is progressing in severity.
- Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study, including any condition that could interfere with the accurate assessment and recovery of [14C].
- History or presence of hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A
Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of GW786034
|
oral, 800 mg
Other Names:
oral, 400 mg radiolabeled
Other Names:
|
Experimental: Part B
characterize the pharmacokinetics of a single IV dose of GW786034
|
oral, 800 mg
Other Names:
IV, 5 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part A: excretion of radioactivity
Time Frame: over 168 hrs
|
over 168 hrs
|
Part B: Plasma pazopanib, clearance (CL) and AUC(0-t), AUC(0-8),Cmax and half-life (t1/2) pazopanib and pazopanib metabolites (GSK 1268992, GSK1268997, GSK1071306 and GW700201)
Time Frame: over 48 hrs
|
over 48 hrs
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part A: Blood and plasma total radioactivity AUC(0-t), AUC(0-8),Cmax and t1/2
Time Frame: over 168 hrs.
|
over 168 hrs.
|
Part B: Safety parameters
Time Frame: over 48 hrs.
|
over 48 hrs.
|
Blood and plasma total radioactivity AUC(0-t), AUC(0-∞), Cmax and t1/2 following oral administration of 400 mg of [14C]-pazopanib containing approximately 70 µCi of radioactivity.
Time Frame: on Day 15 of Cycle 1.
|
on Day 15 of Cycle 1.
|
Samples (for use in a separate study) to characterize and quantify metabolites of pazopanib in plasma, urine and feces.
Time Frame: on Day 15 of Cycle 1.
|
on Day 15 of Cycle 1.
|
Blood:plasma ratio of total drug-related material (radioactivity).
Time Frame: on Day 15 of Cycle 1.
|
on Day 15 of Cycle 1.
|
Plasma pazopanib AUC(0-t), AUC(0-∞), Cmax, tmax following oral administration of 400 mg of [14C]-pazopanib containing 70 µCi of radioactivity.
Time Frame: on Day 15 of Cycle 1.
|
on Day 15 of Cycle 1.
|
Safety parameters: adverse events (AEs), vital signs, electrocardiograms (ECGs) and clinical laboratory assessments.
Time Frame: on Day 15 of Cycle 1.
|
on Day 15 of Cycle 1.
|
Plasma pazopanib AUC(0-24), Cmax, tmax following oral administration of 800 mg pazopanib
Time Frame: on Day 15 of Cycle 1.
|
on Day 15 of Cycle 1.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VEG10004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Renal Cell
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
Clinical Trials on GW786034, oral
-
National Cancer Institute (NCI)WithdrawnSarcoma | Osteosarcoma | Brain Tumor | Neuroblastoma | Wilms TumorUnited States
-
GlaxoSmithKlineCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Neoplasms, OvarianUnited States, Australia, Singapore
-
Illinois CancerCare, P.C.TerminatedNon Small Cell Lung CancerUnited States
-
Illinois CancerCare, P.C.TerminatedProstate CancerUnited States
-
GlaxoSmithKlineCompletedCarcinoma, Renal CellUnited States
-
Washington University School of MedicineNovartisTerminatedNon-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell LungUnited States
-
The Netherlands Cancer InstituteGlaxoSmithKlineCompletedSarcoma,Soft TissueNetherlands
-
GlaxoSmithKlineCompletedCarcinoma, Renal CellUnited States, Australia
-
Novartis PharmaceuticalsChildren's Oncology GroupCompletedSolid TumoursUnited States, Canada, Hungary, Spain, France, Slovakia, Czechia
-
GlaxoSmithKlineCompletedCarcinoma, Renal CellUnited States, Taiwan, Belgium, Israel, Australia, Hong Kong, China, Czech Republic